Hims Daily (Jul 14, 2025)

ANDREW DUDUM REPLIES TO NIGHTHAWK: "🤣"

Jonathan Stern

Jul 14, 2025

Today: +$4.14 (+8.64%)
YTD: +$27.85 (+115.18%)
Q3: +$2.18 (+4.37%)

🔥 ICYMI - here’s our FINAL Hims Data Tracker of Q2.

What’s Happening

Shares surged nearly +9% to kick off the week, reclaiming the $50 level early and grinding higher all the way into the close.
- Volume was just 33M
The Washington Post dropped a spicy story on the Hims-Novo breakup. CEO Andrew Dudum says Hims made it clear to Novo they would continue compounding semaglutide — and got no pushback. So when Novo abruptly pulled the plug, it completely “blindsided” the team. The story also revealed that the two companies were working on a white-labeled Wegovy product under the Hims brand.
- According to the article - just days before the breakup, Novo’s U.S. chief Dave Moore sent Dudum a friendly Father’s Day note. It’s a gesture that makes the sudden fallout even more jarring.
This past weekend, whispers began to circulate that HIMS paid €300M (~$350M) for ZAVA at roughly 3x revenue. No 8-K yet, so still unconfirmed. But if true, it would leave Hims with nearly $1B left in cash.
Comprehensive lab testing is now “coming soon,” per this page on the Hims website. It teases at-home testing across 100+ biomarkers (heart, hormone, thyroid, prostate, liver), all powered by its Trybe Labs acquisition. Think Function Health and Superpower - but available through the Hims super-app. It’s a clear signal Hims is positioning itself to be a leader in personalized diagnostics.
Technicals turned bullish. Shares closed above both $50 and the 20-day EMA. With ~38% of the float now sold short, some investors think the stock may be setting up for a run into earnings.
DUDUM ENTERS THE TIMELINE. On Sunday, Andrew replied “🤣” to a tweet from the Hims- and ASTS-obsessed account “Nighthawk Capital” that summoned the CEO with a gopher GIF asking about TRT and menopause timelines. Some investors saw the response as a wink - and a bullish sign that announcements may be coming soon.
Morgan Stanley flagged a Y/Y decline in app downloads, citing internal Alphawise data. The market shrugged. Similarweb data tells a different story about website traffic, showing +31% growth in web traffic Y/Y for June.